|Mr. J. David Enloe Jr.||Pres, CEO & Director||976.25k||N/A||1964|
|Mr. Ryan D. Lake CPA||Chief Financial Officer||717.33k||N/A||1977|
|Mr. Marshall Rizzo M.B.A.||Sr. VP of Operations||N/A||N/A||N/A|
|Mr. Richard Sidwell Ph.D.||VP & Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Cristin Grove||VP of Sales||N/A||N/A||N/A|
|Ms. Erica Raether M.A.||VP of People, Culture & ESG||N/A||N/A||N/A|
|Mr. Randall J. Mack||Sr. VP of Devel.||N/A||N/A||1965|
|Mr. Eduardo Uribe||Head of Quality of San Diego||N/A||N/A||N/A|
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Societal CDMO, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 8; Compensation: 8.